Veracyte, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value and what the price assumes
Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.
Starts at revenue growth over the last three years, 20.4% a year (statements).
US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).
Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.
Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.
Debt or cash not on file: 0 to start with.
What today's price assumes
A market value of $3.7 B means free cash flow growing 20.0% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.
Revenue grew 20.4% a year over the last three years.
Against the market value, for other rates
Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.
| Discount rate ↓ / growth → | 15.37% | 17.87% | 20.37% | 22.87% | 25.37% |
|---|---|---|---|---|---|
| 7.92% | +4% | +25% | +52% | +83% | +120% |
| 8.92% | -15% | +2% | +23% | +48% | +78% |
| 9.92% | -29% | -14% | +3% | +23% | +48% |
| 10.92% | -39% | -27% | -12% | +5% | +25% |
| 11.92% | -47% | -36% | -24% | -10% | +7% |
On one scale
Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.
Your own DCF model
A full discounted-cash-flow model of Veracyte, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Biotechnology
Multiples of its companies with a market value at most 60 days old, times Veracyte, Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | Veracyte, Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| P/E | 9.4× / 19.7× / 59.0× | 29.4× | net income $66 M | $625 M to $3.9 B | 33 |
| Price to sales | 2.2× / 5.0× / 10.2× | 6.4× | revenue $517 M | $1.2 B to $5.2 B | 84 |
| Price to book | 3.2× / 4.6× / 13.1× | 2.9× | book equity $1.3 B | $4.2 B to $17.1 B | 69 |
Against its own history
Veracyte, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
P/E
32.6×Now below its median of 64.9×, in the bottom quarter of its range; range 27.9× to 124.4× over 21 months.
Price to sales
6.6×Now close to its median of 6.5×; range 4.2× to 23.4× over 30 months.
Price to book
2.9×Now above its median of 2.6×; range 1.6× to 16.7× over 30 months.
As of Oct 22, 2026
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $517 M | $66 M | $136 M | $10 M | $127 M | — | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $446 M | $24 M | $75 M | $11 M | $64 M | — | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $361 M | $-74 M | $44 M | $10 M | $34 M | — | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $297 M | $-37 M | $8 M | $9 M | $-1 M | — | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $220 M | $-76 M | $-32 M | $5 M | $-37 M | $-173 M | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $117 M | $-35 M | $-10 M | $3 M | $-13 M | $-349 M | SEC annual report (10-K, 20-F) |